Neurostimulation Therapy Articles & Analysis
18 news found
FDA Breakthrough Device Designation for the treatment of adult patients with moderate to severe OSA and Complete Concentric Collapse (CCC) of the soft palate in September; engaged in sprint discussions with FDA regarding the IDE study for CCC patients in the U.S., which Nyxoah hopes to commence in the second half of 2022 Received expanded CE Mark indication to treat CCC patients in October, thus ...
“We are very pleased that we are able to put this litigation behind us, while maintaining our current menu of therapy options,” said Earl Fender, CEO. Nalu is a California-based company with miniaturized, commercially available neurostimulation implants for chronic intractable pain management. ...
The Nalu neurostimulation system was designed to address major unmet needs in the treatment of chronic neuropathic pain and provide a differentiated value proposition for patients and physicians. About the Nalu Neurostimulation System The proprietary Nalu neurostimulation system consists of a fully-featured, battery-free, miniaturized IPG ...
Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. ...
Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. ...
Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. ...
Cleared for the spinal cord stimulation and peripheral nerve stimulation indications, the Nalu mIPG is uniquely powered wirelessly by an external Therapy Disc containing a battery and controlled by the patient via a smartphone-based app. ...
“Each Nalu product is engineered to be more livable, durable and adaptable for our patients, so we are able to meet their needs at every stage and step of their pain management journey.” The Nalu Neurostimulation System features a micro-Implantable Pulse Generator (mIPG) which is powered wirelessly by a wearable, external Nalu Therapy Disc. ...
With previous research from my group, bilateral stimulation seems to open the soft palate even with CCC. Bilateral neurostimulation solution is a new hope for these patients in need for a safe and efficient therapy. ...
Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. ...
Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. ...
Nyxoah’s lead solution is the Genio® system, a CE-validated, patient-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke. ...
Our Nalu Neurostimulation System, or Nalu System, delivers gentle electrical pulses to the nervous system to modulate pain signals to the brain. We designed our Nalu System to address major unmet needs in the treatment of chronic neuropathic pain and provide a differentiated value proposition for patients and physicians. About the Nalu Neurostimulation System ...
“We aim to accelerate developments in the emerging field of bioelectronics by boosting the novel modality of selective neurostimulation,” said Laura Matz, Chief Science and Technology Officer of Merck. ...
Dublin – Ireland, 29 June 2021 – Mainstay Medical Holdings plc (the “Company”) today announced the limited commercial launch in the U.S. of ReActiv8, its implantable Restorative Neurostimulation™ system to treat intractable chronic low back pain. ...
“Part of our lifetime commitment to patients and physicians includes providing access to the latest advancements in neurostimulation therapies through software upgrades,” said Earl Fender, Nalu’s President and CEO. “With this latest upgrade, we offer an expanded menu of therapy options to help people suffering with ...
Lewis and the Perth team for getting this manuscript published, since this is the first and promising step towards offering hypoglossal nerve stimulation to a cohort of OSA patients who are currently excluded from such therapy. We will be announcing the full results of our BETTER SLEEP study in May ...
Nyxoah’s lead solution is the Genio® system, a CE-validated, patient-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk1 and comorbidities including cardiovascular diseases, depression and stroke. ...